Guided Therapeutics, Inc. (GTHP)
Stock Price:
$0.405 USD
0.080 (24.62%)
Updated Oct 20, 2020 12:51 PM EDT - Market open
Key Info
| Market Cap |
5.30M |
| Revenue (ttm) |
17,000 |
| Net Income (ttm) |
-3.09M |
| Shares Out |
13.10M |
| EPS (ttm) |
-0.53 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 20, 2020 |
| Last Price |
$0.405 |
| Previous Close |
$0.325 |
| Change ($) |
0.080 |
| Change (%) |
24.62% |
| Day's Open |
0.340 |
| Day's Range |
0.340 - 0.405 |
| Day's Volume |
957 |
| 52-Week Range |
0.1005 - 0.58 |
More Stats
| Market Cap |
5.30M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
13.10M |
| Float |
6.67M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.53 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
0.84 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
312.00 |
| PB Ratio |
n/a |
| Revenue |
17,000 |
| Operating Income |
n/a |
| Net Income |
-3.09M |
| Free Cash Flow |
n/a |
| Net Cash |
n/a |
| Net Cash / Share |
n/a |
| Gross Margin |
-200.00% |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-100.15% |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Overview
No financial data available for this stock yet.
Company Details
| Full Name |
Guided Therapeutics, Inc. |
| Country |
United States |
| Employees |
5 |
| CEO |
Gene S. Cartwright |
Stock Information
| Ticker Symbol |
GTHP |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
OTCMKTS: GTHP |
| IPO Date |
July 1, 1997 |
Description
Guided Therapeutics, a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was founded in 1992 and is based in Norcross, Georgia.